This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


ViciniVax BV

Drug Names(s): SFVeE6,7

Description: ViciniVax developed Vvax001 based on an attenuated, recombinant Semliki Forest virus (SFV). Vvax001 is a therapeutic cancer vaccine against (pre)malignant cervical lesions.

Deal Structure: ViciniVax and Intravacc
In March 2013, Intravacc, the Institute for Translational Vaccinology, and ViciniVax announced that they signed a license agreement on the use of Intravaccs Vero production cell line for vaccine development.

Under the terms of the agreement, ViciniVax will have a non-exclusive license to use the Vero cell line platform technology of Intravacc for development of a therapeutic vaccine against cervical cancer Vvax001. In addition, ViciniVax will receive master and working cell banks.

Partners: Intravacc (Institute for Translational Vaccinology)

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug